Scripps spin-out Vividion launches with $50M
A startup from the Scripps Research Institute has raised a $50 million Series A to "expand the druggable proteome." Led by ARCH and Versant Ventures, the sizeable investment reflects the potential of both the platform and the countless therapeutic candidates it could produce.